1.EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Program. Eur Heart J 2011;22(7):554-72. DOI:10.1053/euhj.2011.2610.2.Eastaugh J.L., Calvert M.J., Freemantle N. Highlighting the need for better patient care in stable angina: results of the international Angina Treatment Patterns (ATP) Survey in 7074 patients. Fam Pract. 2015;22(1):43-50. DOI:10.1093/fampra/cmh711.3.Kotseva K., De Backer G., De Bacquer D., et al. Lifestyle and impact on cardiovascular riskfactor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019;26(8):824-35. DOI:10.1177/ 2047487318825350.4.Kumbhani D. J., Fonarow G. C., Cannon C. P., et al. Get With the Guidelines Steering Committee and Investigators. Temporal trends for secondary prevention measures among patients hospitalized with coronary artery disease. Am J Med. 2015;128(4):426.e1-9. DOI:10.1016/j.amjmed.2014.11.013.5.Tolpygina S.N., Martsevich S.Yu. Study of the dynamics of the frequency of taking the main classes of drugs indicated in the treatment of patients with chronic ischemic heart disease, from 2004 to 2014. Data from the registry PROGNOSIS OF CHRONIC HEART DISEASE. Clinician.2016; 10(1):29-35]. DOI: 10.17650/ 1818-8338-2016-10-1-29-35.